Pulmonary arterial hypertension (PAH) seems to be a rare and specific complication of treatment with dasatinib . It is diagnosed relatively late, several months after the start of dasatinib therapy and the predictive symptom is usually pleural effusion, sometimes pericardial effusion.
The initial results of clinical trials did not indicate that this complication could become an important clinical problem. In the DASISION study, symptoms of PAH were diagnosed only in 1.2% of patients treated with dasatinib because of chronic myeloid leukemia (CML), and nobody was excluded from therapy .
Click here to view the full article in Future Oncology.